Gurugram-based healthcare edtech startup Virohan is gearing up to raise USD 3 million (~INR 25.7 crore) in fresh capital, as part of its ongoing pre-Series B round, once again led by Blume Ventures, according to some reports. This marks the latest in a series of strategic infusions aimed at bolstering the company’s expansion and operational capabilities in the fast-evolving vocational training space.
Deal Structure and Investor Participation
The Virohan board has passed a special resolution to issue 1,783 CCPS (compulsory convertible preference shares) at a price of INR 1,44,072 per share, confirming the upcoming raise. The funding round sees participation from existing backers:
- Blume Ventures: INR 15 crore
- Bharat Inclusive Technologies: INR 5.7 crore
- Rebright Partners (Japan): INR 5 crore
This investment round builds upon earlier tranches of the pre-Series B round that kicked off in December 2022. Notably, in February 2024, Virohan had raised USD 1.8 million (~INR 14.9 crore) in a pre-Series B2 extension also led by Blume Ventures, with contributions from MS&AD Ventures (Mitsui Sumitomo Insurance Venture Capital), Suneight OK Partnership, and other strategic and angel investors.
Valuation Uplift and Stakeholder Impact
Post this latest allotment, Virohan’s valuation is projected to reach INR 530 crore (~USD 62 million), reflecting a 25% jump from the USD 51 million (~INR 425 crore ) valuation estimated during its previous raise in early 2024. The updated cap table positions Blume Ventures as the largest external shareholder with a 15.36% stake, followed by:
- Bharat Inclusive Technologies: 5.84%
- Rebright Partners: 5.65%
Co-founders Kunaal Dudeja, Nalin Saluja, and Archit Jayasal will each retain approximately 13.6% equity following the capital infusion.
Funding Timeline and Strategy
Virohan’s funding journey underscores a steady climb in investor confidence:
- Jan 2023: USD 7 million raised (pre-Series B1), led by Blume Ventures
- Feb 2024: USD 1.8 million (pre-Series B2)
- May 2025: USD 3 million (pre-Series B3, ongoing)
This brings Virohan’s total funding to nearly USD 18 million, having previously raised from investors including Rebright Partners, ALES Japan, AngelList, Elea Foundation, and several prominent angel investors.
Business Model and Performance
Founded in 2018, Virohan operates at the intersection of education technology and healthcare skilling, offering hybrid vocational training programs for paramedical and allied healthcare roles — including medical lab technicians, emergency medical technicians, radiology technicians, and more.
The company trains students across more than 20 campuses and online platforms in cities such as Delhi, Gurugram, Pune, Jaipur, Mumbai, and Nagpur. It has recently partnered with Lenskart to launch ‘SureStart’, a domain-specific training program in ophthalmic care.
Operationally, Virohan has shown impressive top-line growth:
- FY22: INR 6.5 crore revenue
- FY23: INR 10.65 crore (63.8% growth)
- FY24: INR 21 crore (nearly 2x YoY)
However, the company’s losses have widened in parallel:
- FY22: INR 12.96 crore
- FY23: INR 18.58 crore
- FY24: INR 22 crore (18% increase)
Despite the burn, Virohan maintains strong completion (96%) and placement (98%) rates for its programs, showcasing tangible student outcomes — a key metric in the impact-focused edtech ecosystem.
Market Outlook and Expansion Plans
With a chronic shortage of skilled healthcare workers — a gap further highlighted during the COVID-19 pandemic — Virohan is strategically placed to address a critical human capital deficit in India’s healthcare infrastructure.
Looking ahead, the company aims to:
- Expand to 200+ campuses pan-India
- Develop multilingual content and omnichannel infrastructure
- Train over 10,000 students over the next 18 months
- Explore international markets, notably Japan, leveraging support from ALES and Rebright
Conclusion
Virohan’s ongoing fundraising momentum, rising valuations, and deepening investor alignment mark it as one of India’s most promising edtech plays in the healthcare sector. As the startup navigates scale and sustainability, its focus on outcomes, employability, and tech-enabled delivery positions it to potentially lead the transformation of vocational healthcare training — both domestically and abroad.
For more details related to IPO GMP, SEBI IPO Approval, and Live Subscription stay tuned to IPO Central.